It would be highly relevant to examine mutation and gene expression data from large cohorts of RR-DLBCL tumors obtained prior to platin-based treatment to determine whether XPA and ERCC6 can serve as prognostic biomarkers for the clinical outcomes of RR-DLBCL patients. This evidence concerns the gene ERCC6 and diffuse large B-cell lymphoma.